内分泌治疗联合唑来膦酸对前列腺癌骨转移疗效观察

Clinical Efficacy Observation of Hormone Treatment Combined with Zoledronic Acid for the Bone Metastasis of Prostatic Cancer

目的：探讨内分泌治疗联合唑来膦酸对前列腺癌骨转移及骨痛的疗效。方法：选取2010年1月-2015年6月在笔者所在医院住院的前列腺癌骨转移患者50例,所选患者均采用唑来膦酸联合内分泌治疗,观察治疗后效果。结果：治疗后止痛总有效率为92%。治疗前,血清PSA为20~100 ng/ml的患者12例,血清PSA≥100 ng/ml的患者38例;治疗后,38例患者的PSA≤4 ng/ml,2例患者的PSA在4~10 ng/ml之间,7例患者的PSA在10~50 ng/ml之间,仅3例患者的PSA≥50 ng/ml。不良反应为潮热、乳房胀痛、轻度的发热、血小板降低、胃肠道不适,经对症处理后逐渐缓解。结论：内分泌治疗联合唑来膦酸对前列腺癌骨转移及骨痛的治疗是有效的、安全的。

Objective： To explore the efficacy of hormone treatment combined with Zoledronic Acid for the ostalgia and bone metastasis of prostatic cancer. Method： Fifty patients who were diagnosed with bone metastasis of prostatic cancer in our hospital from January 2010 to June 2015 received Zoledronic Acid and hormone treatment.The treatment effect was observed.Result： After treatment, the total effective rate of analgesia was 92%.Before treatment, the serum PSA of 12 patients were 20-100 ng/ml, 38 patients were ≥100 ng/ml.After treatment, the serum PSA of 38 patients was ≤4 ng/ml, 2 patients were 4-10 ng/ml, 7 patients were 10-50 ng/ml, only 3 patients were ≥50 ng/ml.Adverse reactions were hot flashes, breast tenderness, mild fever, thromboeytopenia and gastrointestinal discomfort, after symptomatic treatment the adverse reactions above gradually eased.Conclusion： Hormone treatment combined with Zoledronie Acid is effective and safe in the treatment of bone metastasis of prostatic cancer.